3个月时评估转录水平即可预测接受酪氨酸激酶抑制剂治疗的慢性粒细胞性白血病患者的结局

Assessment of Transcript Levels at 3Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
2012-08-14 15:50点击:111次发表评论
作者:"David Marin⇓, Amr R. Ibrahim, Claire Lucas, Garet 【View at publisher】 【全球专家评论】
期刊: J Clin Oncol2012年1月3期30卷 专家评级: 循证评级:A

Purpose:

We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in chronic phase (CML-CP) at 3, 6, and 12months after starting imatinib to identify molecular milestones that would predict for overall survival (OS) and other outcomes more reliably than serial marrow cytogenetics.

Patients and Methods:

We analyzed 282 patients with CML-CP who received imatinib 400mg/d as first-line therapy followed by dasatinib or nilotinib if treatment with imatinib failed. We used a receiver operating characteristic curve to identify the cutoffs in transcript levels at 3, 6, and 12months that would best predict patient outcome. We validated our findings in an independent cohort of 95 patients treated elsewhere.

Results:

Patients with transcript levels of more than 9.84% (n=68) at 3months had significantly lower 8-year probabilities of OS (56.9% v 93.3%; P<.001), progression-free survival, cumulative incidence of complete cytogenetic response, and complete molecular response than those with higher transcript levels. Similarly, transcript levels of more than 1.67% (n=87) at 6months and more than 0.53% (n=93) at 12months identified high-risk patients. However, transcript levels at 3months were the most strongly predictive for the various outcomes. When we compared OS for the groups defined molecularly at 6 and 12months with the usual cytogenetic milestones, categorization by transcript numbers was the only independent predictor for OS (relative risk, 0.207; P<.001 and relative risk, 0.158; P<.001, respectively).

Conclusion:

A single measurement of BCR-ABL1 transcripts performed at 3months is the best way to identify patients destined to fare poorly, thereby allowing early clinical intervention.

学科代码:肿瘤学 血液病学   关键词:3个月时评估转录水平即可预测接受酪氨酸激酶抑制剂治疗的慢性粒
来源: Eclips
Eclips介绍:Eclips由权威专家阅读世界顶级医学期刊(包括New England Journal of Medicine, The Lancet, JAMA, BMJ 等)后筛选出最顶尖的文章,并总结、分级和点评,为繁忙的临床医生提供最快、最有效的前沿医学信息,并同时提供临床医生参与点评文献和同行互动交流的学术平台。 请点击申请试用并填写联系信息,我们将每月为前100位申请者发送带有用户名、密码及网页链接的电子邮件,请您注意查收!感谢您的参与及使用! 马上访问Eclips网站http://eclips.consult.com/
顶一下(0
您可能感兴趣的文章
    发表评论网友评论(0)
      发表评论
      登录后方可发表评论,点击此处登录